Latest Commercialization News

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.

Omega Oil and Gas has bolstered its balance sheet with a $46 million equity placement and confirmed the strong commercial potential of its Canyon Project, setting the stage for a major appraisal campaign in 2026.

Premier1 Lithium reports its first inferred gold Mineral Resource at Wadgingarra and a new high-grade gold discovery at Rochefort, alongside a $1.84 million entitlement offer to fund exploration.

McPherson’s Limited updates shareholders on its ongoing transformation journey, reporting modest core brand growth in FY25 and outlining a strategic outlook for FY26 focused on sustainable expansion and operational efficiency.

Acrux Limited reports robust revenue growth in Q1 FY26, driven by strong profit share income from recently launched topical pharmaceuticals and a significant R&D tax rebate repayment.

Spenda Limited reported a record $204 million in payment volumes for Q1 FY26 alongside a strategic cost reduction of 21% annualised. The quarter also saw a significant leadership change with the resignation of its Managing Director.

KALiNA Power advances its Alberta AI data centre power projects with a significant CAD 18 million transfer of assigned megawatts and engages bankers to fund development capital.

EVE Health Group has taken significant strides in commercialising its women’s and men’s health products Dyspro™ and Libbo™, securing regulatory clearances, first patient prescriptions, and raising $1.1 million to support market expansion.

Galilee Energy reported steady cash reserves and ongoing reservoir pressure monitoring at its Glenaras Gas Project, while exploring new funding and growth opportunities.

Vitasora Health Limited reported robust patient program growth and secured new US partnerships, driving revenue above A$1 million for the quarter. A recent A$11 million capital raise positions the company for continued expansion and cash-flow breakeven by late 2026.

Hastings Technology Metals and Wyloo have signed a non-binding agreement with Ucore Rare Metals to negotiate a long-term offtake for rare earth concentrate and explore US-based downstream processing.

Imugene Limited reports an 81% overall response rate in its azer-cel CAR T-cell therapy trial for difficult lymphomas, alongside a $25 million capital raise that extends its cash runway to mid-2027.